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Dear Sir,
We appreciate the interest of Dr. Durand and colleagues in
our study “In vivo radionuclide uptake quantification using
a multi-pinhole SPECT system to predict renal function in
small animals” [1], in which we showed a high agreement
between the radioactivities determined in vivo by SPECT
and ex vivo in a gamma counter. We would like to take this
opportunity to respond to their specific comments:
1. Concerning statistics, Durand et al. suggest that the
standard error of estimate would have been more
appropriate for analysis of our data. We agree that the
regression analysis that we used was somewhat
rudimentary. However, the article referred to [2]
describes the comparison of two indirect, unrelated
measurement methods with an unknown true value. In
contrast, in our study we compared radioactivity levels
determined in vivo by SPECT with values determined
ex vivo in the gamma counter. In this experimental
setting, the gamma counter is our gold standard. In our
opinion the regression analysis appears to be the right
method; however, indication of the confidence and
prediction intervals of the regression curve would have
improved the significance. We indicate these values in
Fig. 1 of this reply.
2. In the second paragraph of their letter [3], Durand et al.
dispute whether it is possible to assess renal function
with the technique described, as they do not consider
absolute DMSA uptake a valid marker for renal
function. We are convinced that the new technique,
multi-pinhole SPECT, can indeed be used to assess
renal function in vivo. The reference given [4]
describes considerable overestimations of renal func-
tion in a model assuming unilateral kidney function
impairment. However, the use of high-dose peptide
receptor radionuclide therapy (PRRT) with [
177Lu-
DOTA
0,Tyr
3]octreotate results in a symmetrical reduc-
tion of renal function. Therefore, the model cited [4]
does not apply to our experimental setting. Further-
more, we found a convincing relation between the
99mTc-DMSA uptake and 1/creatinine (r
2=0.772,
p<0.001) (Fig. 2) as well as a relation between the
reduction of
99mTc-DMSA uptake and total protein
excretion into the urine in rats [5, 6], showing the value
of
99mTc-DMSA in assessing renal function after PRRT.
Neither in the title nor in the introduction had we
focussed exclusively on
99mTc-DMSA. The aim of this
work was to validate NanoSPECT for the assessment of
renal function in vivo after PRRT.
99mTc-DMSA appeared
to be a suitable tracer for this purpose. However, the high
sensitivity of the camera allows the acquisition times to be
kept very short, which in turn allows dynamic SPECT
imaging. Therefore it is, for example, also possible to
acquire and quantify dynamic
99mTc-MAG3 SPECT images
[7]. Considering the whole collection of tracers available, it
would be possible to investigate and quantify different
aspects of renal function in vivo with the technique
described, as indicated in the title of our manuscript [1].
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Jülich, Germany3. We fully agree that the description of the pharmacoki-
netics of
99mTc-DMSA was somewhat basic. This was
done because our manuscript is a short communication
to prove a principle and to demonstrate the potential of
a new technique.
99mTc-DMSA was not the main focus
of this article.
The renal handling of
99mTc-DMSA is the source of
controversy, and besides peritubular uptake several authors
have reported tubular reabsorption as well [8, 9].
4. As stated in the fourth paragraph of the letter from
Durand et al., it has indeed been questioned whether
99mTc-DMSA is a marker of tubular function. It is,
however, indisputable that
99mTc-DMSA is a marker
for functioning tubules. Again, we would like to point
out that we found a very good relation between
99mTc-
DMSA uptake and generally accepted clinical markers.
We therefore believe that
99mTc-DMSA is an excellent
marker to quantify renal function in rats after high-dose
PRRT with [
177Lu-DOTA
0,Tyr
3]octreotate and we shall
continue to use this technique in this setting.
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Fig. 1 Linear regression analy-
sis of the data from [1], with
indication of the 95% confi-
dence interval (CI) and the
prediction interval (PI)
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Fig. 2 Linear correlation of percentage injected activity (%IA) in the
left kidney 4 h after injection of 50 MBq
99mTc-DMSA measured with
NanoSPECT (x-axis) and 1/creatinine values (y-axis) in rats treated
with 278 or 555 MBq [
177Lu-DOTA
0,Tyr
3]octreotate with or without
amifostine or D-lysine as renoprotective drugs [6]
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